The Europe Recombinant Proteins Market was valued at $577.9 Million in 2023 and projected to reach to $803.4 Million by 2028, representing a compound annual growth rate of 6.8%. Europe's recombinant proteins market is positioned for steady expansion through 2028, supported by increasing prevalence of chronic diseases, growing demand for biologic therapeutics, and expanding applications in oncology, immunology, and rare diseases.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe's recombinant proteins market reached $577.9 million in 2023 and is forecast to grow to $803.4 million by 2028, representing a steady 6.8% CAGR, demonstrating sustained demand across the region.
Europe benefits from world-class research institutions, manufacturing facilities, and a mature biopharmaceutical ecosystem that supports innovation and commercialization of recombinant protein therapeutics.
The European Medicines Agency (EMA) provides stringent yet efficient regulatory pathways, ensuring high-quality recombinant protein products and fostering investor confidence in the European market.
Significant biotechnology research funding and public-private partnerships across European nations drive continuous innovation in recombinant protein development and therapeutic applications.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Recombinant cytokines and growth factors from its Gibco, Invitrogen, and PeproTech brands are used in cell culture, drug discovery, immunology research, stem cell expansion, and cell therapy manufacturing. Its GMP-grade proteins support the production of cell-based therapies. | Supports reproducible cell culture and immune-cell expansion | Enables research-to-manufacturing workflows | Supports clinical manufacturing requirements through GMP-grade proteins. |
|
|
Merck provides recombinant protein expression and process-development technologies for biopharmaceutical applications. Its CHOZN expression platform and associated process-development services support the development and scale-up of recombinant proteins and other biologics. | Supports high-producing cell-line development | Facilitates process optimization and scale-up | Helps improve manufacturing productivity and consistency. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2023 |
| Fastest Growing Segment | INTERFERONS (IFNS) (Type) |
| Forecast Period | 2023-2028 |
| Growth Rate | CAGR of 7.2% from 2023 to 2028 |
| Largest Segment | PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES (End User) |
| Market Size Base Year (Billions) | ~USD 2.26 (2023) |
| Revenue Forecast (Billions) | ~USD 3.2 (2028) |
| Segments Covered | Product, Type, Application, Host Cell, End User |
5 segment dimensions are covered across the global market.
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC RESEARCH INSTITUTES | 26.7 | 27.3 | 28.2 | 29.4 | 30.8 | 32.3 | 34.1 | 35.9 | 5 |
| BIOTECHNOLOGY COMPANIES | 18.7 | 19.1 | 19.7 | 20.5 | 21.5 | 22.5 | 23.7 | 25 | 4.8 |
| CONTRACT RESEARCH ORGANIZATIONS | 9.9 | 10 | 10.3 | 10.7 | 11.2 | 11.7 | 12.3 | 12.9 | 4.6 |
| OTHER END USERS | 6.4 | 6.5 | 6.6 | 6.8 | 7 | 7.3 | 7.5 | 7.8 | 3.5 |
| PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES | 52.4 | 53.6 | 55.6 | 58 | 60.8 | 63.9 | 67.5 | 71.3 | 5.1 |
| TOTAL | 114.11 | 116.47 | 120.44 | 125.47 | 131.23 | 137.71 | 145.09 | 152.97 | 4.9 |
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC RESEARCH INSTITUTES | 124.5 | 128.6 | 135.4 | 143.6 | 153 | 163.6 | 175.7 | 188.8 | 6.9 |
| BIOTECHNOLOGY COMPANIES | 87.4 | 90.2 | 94.8 | 100.4 | 106.8 | 114 | 122.3 | 131.3 | 6.7 |
| CONTRACT RESEARCH ORGANIZATIONS | 46 | 47.3 | 49.6 | 52.4 | 55.6 | 59.3 | 63.4 | 67.9 | 6.5 |
| OTHER END USERS | 29.5 | 30 | 31.1 | 32.6 | 34.2 | 36 | 38.1 | 40.3 | 5.3 |
| PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES | 244.7 | 253.3 | 267 | 283.6 | 302.6 | 324 | 348.5 | 375.1 | 7 |
| TOTAL | 531.99 | 549.41 | 577.93 | 612.64 | 652.24 | 696.92 | 747.9 | 803.41 | 6.8 |
| Country | 2025 size (native) |
|---|---|
| Germany | USD 10.6 Million |
| United Kingdom | USD 62.8 Million |
| France | USD 6.5 Million |
| Italy | USD 2.7 Million |
| Spain | USD 1.7 Million |
| Rest Of Europe | USD 54.9 Million |
Europe's recombinant proteins market was valued at $577.9 million in 2023 and is expected to grow to $803.4 million by 2028.
Europe's recombinant proteins market is projected to grow at a compound annual growth rate (CAGR) of 6.8% from 2023 to 2028.
Oncology, immunology, and rare disease segments are primary drivers of recombinant protein demand in Europe due to high unmet medical needs and advanced treatment protocols.
The European Medicines Agency (EMA) provides harmonized regulatory pathways that facilitate faster approval and commercialization of recombinant protein therapeutics across Europe.
Contract manufacturing organizations in Europe provide critical manufacturing, fill-finish, and quality assurance services that enable biopharmaceutical companies to scale recombinant protein production efficiently.
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global recombinant proteins market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
The secondary sources referred to for this research study include publications from government sources,such as the World Health Organization, The Antibody Society,Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC),National Center for Biotechnology Information (NCBI), American Medical Association (AMA), RecombinantAntibody Network (RAN), National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), and the Institute for Molecular Medicine, corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, professional associations, and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

To know about the assumptions considered for the study, download the pdf brochure
The top-down and bottom-up approaches were used to estimate & validate the total size of the recombinant proteins market. These methods were also used extensively to estimate the size of various market segments.

After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data were triangulated by analyzing various factors and trends from the demand and supply sides.
Recombinant proteins are manipulated proteins generated by recombinant DNA technology that modifies gene sequences. These are formed by transfecting foreign genes into a host cell. Recombinant proteins are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses. This market includes recombinant protein products, including growth factors, cytokines, recombinant enzymes, structural proteins, and membrane proteins.
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Geographical Analysis
Company Information
Full forecast, segment splits, and company analysis for all Recombinant Proteins Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report